ENDRA Life Sciences Inc. (NASDAQ:NDRA – Get Free Report) was the recipient of a large increase in short interest in the month of October. As of October 15th, there was short interest totalling 717,700 shares, an increase of 167.7% from the September 30th total of 268,100 shares. Approximately 4.0% of the company’s shares are sold short. Based on an average daily trading volume, of 9,790,000 shares, the days-to-cover ratio is presently 0.1 days.
ENDRA Life Sciences Stock Performance
Shares of ENDRA Life Sciences stock opened at $0.28 on Friday. The stock has a 50 day moving average of $0.28 and a 200 day moving average of $284.82. The firm has a market capitalization of $4.84 million, a price-to-earnings ratio of -0.01 and a beta of 0.79. ENDRA Life Sciences has a fifty-two week low of $0.18 and a fifty-two week high of $139.50.
ENDRA Life Sciences (NASDAQ:NDRA – Get Free Report) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($4.00) EPS for the quarter, missing the consensus estimate of ($3.50) by ($0.50). Analysts forecast that ENDRA Life Sciences will post -11.08 EPS for the current year.
ENDRA Life Sciences Company Profile
ENDRA Life Sciences Inc develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.
Featured Articles
- Five stocks we like better than ENDRA Life Sciences
- How to Start Investing in Real Estate
- Texas Roadhouse Stock Steering for New Highs This Year
- What is MarketRankā¢? How to Use it
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Are Penny Stocks a Good Fit for Your Portfolio?
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.